- Home
- VNRX vs CUE Comparison
VNRX vs CUE Comparison
Compare VNRX & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNRX
- CUE
- Stock Information
- Founded
- VNRX N/A
- CUE 2014
- Country
- VNRX United States
- CUE United States
- Employees
- VNRX N/A
- CUE N/A
- Industry
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- VNRX Health Care
- CUE Health Care
- Exchange
- VNRX Nasdaq
- CUE Nasdaq
- Market Cap
- VNRX 64.8M
- CUE 59.5M
- IPO Year
- VNRX N/A
- CUE 2018
- Fundamental
- Price
- VNRX $0.63
- CUE $0.74
- Analyst Decision
- VNRX Strong Buy
- CUE Strong Buy
- Analyst Count
- VNRX 4
- CUE 2
- Target Price
- VNRX $3.50
- CUE $3.00
- AVG Volume (30 Days)
- VNRX 200.3K
- CUE 127.4K
- Earning Date
- VNRX 11-13-2025
- CUE 11-13-2025
- Dividend Yield
- VNRX N/A
- CUE N/A
- EPS Growth
- VNRX N/A
- CUE N/A
- EPS
- VNRX N/A
- CUE N/A
- Revenue
- VNRX $1,319,252.00
- CUE $8,286,000.00
- Revenue This Year
- VNRX $274.46
- CUE N/A
- Revenue Next Year
- VNRX $212.60
- CUE $10.19
- P/E Ratio
- VNRX N/A
- CUE N/A
- Revenue Growth
- VNRX 35.10
- CUE N/A
- 52 Week Low
- VNRX $0.40
- CUE $0.45
- 52 Week High
- VNRX $0.94
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- VNRX 46.17
- CUE 37.79
- Support Level
- VNRX $0.57
- CUE $0.77
- Resistance Level
- VNRX $0.73
- CUE $0.79
- Average True Range (ATR)
- VNRX 0.05
- CUE 0.03
- MACD
- VNRX -0.00
- CUE -0.01
- Stochastic Oscillator
- VNRX 37.56
- CUE 11.92
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.